title: Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies.
abstract: Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival. Here, we show that in most cell lines tested, indatuximab ravtansine acts additively or even synergistically with clinically approved therapies for treatment of multiple myeloma. In addition, in vivo mouse xenograft models confirmed the activity of indatuximab ravtansine in combination with lenalidamide and lenalidomide/dexamethasone. Indatuximab ravtansine may therefore be a suitable combination partner for multiple myeloma, and a clinical study is ongoing.
authors.affiliation: Biotest AG, Landsteinerstraße 5, 63303, Dreieich, Germany.
authors.forename: Kurt
authors.initials: K
authors.lastname: Schönfeld
authors.affiliation: Biotest AG, Landsteinerstraße 5, 63303, Dreieich, Germany.
authors.forename: Chantal
authors.initials: C
authors.lastname: Zuber
authors.affiliation: ImmunoGen Inc., 830 Winter Street, Waltham, 02451-1477, MA, USA.
authors.forename: Jan
authors.initials: J
authors.lastname: Pinkas
authors.affiliation: Biotest AG, Landsteinerstraße 5, 63303, Dreieich, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Häder
authors.affiliation: Biotest AG, Landsteinerstraße 5, 63303, Dreieich, Germany.
authors.forename: Katrin
authors.initials: K
authors.lastname: Bernöster
authors.affiliation: Biotest AG, Landsteinerstraße 5, 63303, Dreieich, Germany. christoph.uherek@biotest.com.
authors.forename: Christoph
authors.identifier: 0000-0001-5579-6964
authors.initials: C
authors.lastname: Uherek
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003907:Dexamethasone / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D000077269:Lenalidomide; D008453:Maytansine / Q000031:analogs & derivatives / Q000627:therapeutic use; D051379:Mice; D009101:Multiple Myeloma / Q000188:drug therapy*; D053668:Syndecan-1 / Q000037:antagonists & inhibitors / Q000276:immunology; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; C508241:SDC1 protein, human; D053668:Syndecan-1; C000625392:indatuximab ravtansine; D008453:Maytansine; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide
keywords: Drug combination; Indatuximab ravtansine; Multiple myeloma; Pre-clinical; Tumour regression